Ark's Cerepro clears EMEA validation stage

12 January 2009

London, UK-based Ark Therapeutics says that the Marketing Authorization Application for Cerepro, its novel gene-based therapy for operable  malignant glioma that was recently filed with the European Medicines  Agency (EMEA), has cleared the validation stage. The MAA now commences  formal review via the centralized procedure which is the standard route  for all advanced therapies.

Cerepro was originally filed for marketing approval under exceptional  circumstances in late 2005 and was reviewed by the EMEA with reliance on  Phase II data.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight